RT Journal Article SR Electronic T1 Diagnostic value in colorectal tumorous lesions of SDC2/TFPI2 methylation based on bowel subsite difference JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.22.21252188 DO 10.1101/2021.02.22.21252188 A1 Zhang, Lianglu A1 Dong, Lanlan A1 Lu, Changming A1 Huang, Wenxian A1 Yang, Cuiping A1 Wang, Qian A1 Wang, Qian A1 Lei, Ruixue A1 Sun, Rui A1 Wan, Kangkang A1 Li, Tingting A1 Sun, Fan A1 Gan, Tian A1 Lin, Jun A1 Yin, Lei YR 2021 UL http://medrxiv.org/content/early/2021/02/24/2021.02.22.21252188.abstract AB Background SDC2 methylation is a potential biomarker for colorectal cancer detection with specificity over 90%, but its sensitivity is usually less than 90%. The study aims to improve the sensitivity and specificity by adding TFPI2 methylation as a complement.Methods TFPI2 was identified using colorectal cancer samples from TCGA database with SDC2 methylation level lower than 0.2. SDC2/TFPI2 methylation specific PCR was performed using tissue samples (184 cancer and 54 healthy control) and stool samples (289 cancer, 190 adenoma and 217 healthy control). Detection sensitivity was calculated among tumors from different biopsy locations.Results 88% of 50 TCGA specimens of colorectal cancer with SDC2 methylation level lower than 0.2 showed TFPI2 methylation level higher than 0.2. SDC2/TFPI2 combined detection in stool specimens showed AUC value of 0.98 with the specificity of 96.40% and sensitivity of 96.60% for cancer vs control, AUC value of 0.87 with the specificity of 95.70% and sensitivity of 80.00% for adenoma vs control. The sensitivities were much higher than those of SDC2, and the improvement was most significant in lesions from left colon and rectum.Conclusions This research indicated that the addition of TFPI2 can reduce the miss detection rate of colorectal cancer and adenomas while maintaining high specificity, probably by finding neoplasms in left colon.The method is non-invasive and has good compliance, also avoiding the pain of bowel preparation and risk of cross infection during endoscopy, so it will provide an easy and precise tool for colorectal cancer and its precancerous lesions screening.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is a retrospective study and does not involve clinical trials.Funding StatementThis research is supported by the Department of Health and Family Planning Commission of Jiading District (Grants 2008-ky-01) and Ruijin North Hospital (Grants 2018 zy16). The study was also supported, in part, by grants from the Natural Science Foundation of China (No. 81502461).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical Ethics Committee, Zhongnan Hospital of Wuhan University (ethical approval No.2019099).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlease contact the corresponding author for data requests.